Biomarkers for diagnosis and therapeutic options in hepatocellular carcinoma

Liver cancer is a global health challenge, causing a significant social-economic burden. Hepatocellular carcinoma (HCC) is the predominant type of primary liver cancer, which is highly heterogeneous in terms of molecular and cellular signatures. Early-stage or small tumors are typically treated with surgery or ablation. Currently, chemotherapies and immunotherapies are the best treatments for unresectable tumors or advanced HCC. However, drug response and acquired resistance are not predictable with the existing systematic guidelines regarding mutation patterns and molecular biomarkers, resulting in sub-optimal treatment outcomes for many patients with atypical molecular profiles. With advanced technological…

• UO
  University of Hong Kong
• IA
  Innovation and Technology Fund

  Award: PRP/028/22FX
• UR
  University Research Committee, University of Hong Kong

  Award: 109000349
• HA
  Health and Medical Research Fund

  Awards: 21222151, 19201591, 15162961